Krystal Biotech (KRYS) Stock Rises 32.2%, Indicating Strong Trend
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 12h ago
0mins
Source: NASDAQ.COM
- Price Trend Surge: Krystal Biotech's stock has increased by 32.2% over the past 12 weeks, reflecting investors' sustained willingness to pay more for its potential upside, thereby enhancing market interest in the company.
- Stable Short-Term Performance: A modest 0.9% price increase over the last four weeks indicates that the price trend remains intact, potentially attracting more short-term investors.
- High Trading Signal: Currently trading at 93.3% of its 52-week high-low range, KRYS hints at an impending breakout, which could yield additional returns for investors.
- Strong Fundamental Support: With a Zacks Rank of #1 (Strong Buy), KRYS ranks in the top 5% of over 4,000 stocks, showcasing robust fundamentals driven by earnings estimate revisions and EPS surprises, further bolstering investor confidence.
Analyst Views on KRYS
Wall Street analysts forecast KRYS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRYS is 221.00 USD with a low forecast of 198.00 USD and a high forecast of 255.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 248.910
Low
198.00
Averages
221.00
High
255.00
Current: 248.910
Low
198.00
Averages
221.00
High
255.00
About KRYS
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
